# Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT07682376** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Harbin Medical University** · enrollment: 96 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin
- **DRUG:** Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin

## Key facts

- **NCT ID:** NCT07682376
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-06-10
- **Primary completion:** 2028-05-30
- **Final completion:** 2029-05-30
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-07-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07682376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07682376, "Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07682376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*